CN112641730A - Preparation method of soluble florfenicol powder - Google Patents
Preparation method of soluble florfenicol powder Download PDFInfo
- Publication number
- CN112641730A CN112641730A CN202110189535.8A CN202110189535A CN112641730A CN 112641730 A CN112641730 A CN 112641730A CN 202110189535 A CN202110189535 A CN 202110189535A CN 112641730 A CN112641730 A CN 112641730A
- Authority
- CN
- China
- Prior art keywords
- florfenicol
- parts
- soluble
- cyclodextrin
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 title claims abstract description 108
- 229960003760 florfenicol Drugs 0.000 title claims abstract description 108
- 239000000843 powder Substances 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 38
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 38
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 38
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 38
- 229960004853 betadex Drugs 0.000 claims abstract description 38
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 25
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 25
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 22
- 230000002378 acidificating effect Effects 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000004615 ingredient Substances 0.000 claims abstract description 13
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 18
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 18
- 229960001031 glucose Drugs 0.000 claims description 18
- IIZVTUWSIKTFKO-UHFFFAOYSA-N 2-hydroxypropanoic acid;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound CC(O)C(O)=O.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IIZVTUWSIKTFKO-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 229960001937 trimethoprim lactate Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- YAZSBRQTAHVVGE-UHFFFAOYSA-N 2-aminobenzenesulfonamide Chemical compound NC1=CC=CC=C1S(N)(=O)=O YAZSBRQTAHVVGE-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- NCDOTGFVCDNQNH-UHFFFAOYSA-N O(C)C=1C(=NC(=NC1)N)CC1=CC=CC=C1.C(C(O)C)(=O)O Chemical compound O(C)C=1C(=NC(=NC1)N)CC1=CC=CC=C1.C(C(O)C)(=O)O NCDOTGFVCDNQNH-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 235000019629 palatability Nutrition 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 6
- 235000019658 bitter taste Nutrition 0.000 abstract description 6
- 230000036528 appetite Effects 0.000 abstract description 4
- 235000019789 appetite Nutrition 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method of soluble florfenicol powder, which is prepared from the following raw materials in parts by weight: 5-15 parts of florfenicol, 2-5 parts of beta-cyclodextrin, 3-7 parts of polyethylene glycol, 2-6 parts of silicon dioxide, 2-5 parts of acidic auxiliary materials and 2-3 parts of sterilization ingredients; the florfenicol slow-release taste-masking preparation prepared by the process successfully solves the problem of poor palatability of the florfenicol, masks the bitter taste of the medicament, increases the palatability and greatly improves the appetite of animals; the florfenicol slow-release taste-masking preparation successfully wraps the florfenicol in beta-cyclodextrin, so that the florfenicol can be slowly released, the slow-release effect is achieved, the action time of the florfenicol is prolonged, the curative effect of the florfenicol is improved, and the bioavailability is improved.
Description
Technical Field
The invention relates to the field of soluble florfenicol powder, in particular to a preparation method of soluble florfenicol powder.
Background
Florfenicol is an antibiotic drug, generates broad-spectrum antibacterial action by inhibiting the activity of peptide acyl transferase, and has wide antibacterial spectrum, including various gram-positive bacteria, gram-negative bacteria, mycoplasma and the like. The sensitive bacteria include haemophilus bovis and pig, Shigella dysenteriae, Salmonella, Escherichia coli, pneumococcus, Bacillus influenzae, Streptococcus, Staphylococcus aureus, Chlamydia, Leptospira, Rickettsia, etc.
With the rapid development of the times, more and more people regard animals as spiritual fiducials in the cross-flow of things, and therefore, the health of animals is also crucial to people. The existing soluble florfenicol powder is poor in palatability after being processed by the technology, the bitter taste of the medicine cannot be covered when the soluble florfenicol powder is eaten, and the appetite of animals is greatly reduced.
An effective solution to the problems in the related art has not been proposed yet.
Disclosure of Invention
Aiming at the problems in the related art, the invention provides a preparation method of soluble florfenicol powder, which aims to overcome the technical problems in the prior related art.
Therefore, the invention adopts the following specific technical scheme:
according to one aspect of the present invention, a soluble florfenicol powder is provided.
The soluble florfenicol powder is prepared from the following raw materials in parts by mass:
5-15 parts of florfenicol, 2-5 parts of beta-cyclodextrin, 3-7 parts of polyethylene glycol, 2-6 parts of silicon dioxide, 2-5 parts of acidic auxiliary materials and 2-3 parts of sterilization ingredients.
Wherein the acidic auxiliary materials comprise the following raw material components: 1-2 parts of anhydrous citric acid and 1-3 parts of anhydrous glucose.
Wherein, the composite antioxidant comprises the following raw material components: 0.5-1 part of lactic acid methoxybenzyl aminopyrimidine and 1.5-2 parts of aminobenzene sulfonamide powder.
According to another aspect of the invention, a preparation method of soluble florfenicol powder is provided.
The preparation method of the soluble florfenicol powder comprises the following steps:
s101, weighing florfenicol, beta-cyclodextrin, polyethylene glycol, silicon dioxide, acidic auxiliary materials and sterilization ingredients required by the soluble florfenicol powder according to the mass parts;
s102, preheating a reaction kettle prepared in advance, and preserving heat;
s103, sequentially sieving the weighed florfenicol, trimethoprim lactate and anhydrous citric acid;
s104, sequentially putting the screened florfenicol, the trimethoprim lactate, the anhydrous citric acid and part of anhydrous glucose into a pre-prepared dispersing device for mixing by a dispersing method to obtain a mixture A;
s105, sequentially sieving the weighed beta-cyclodextrin, polyethylene glycol and silicon dioxide;
and S106, sequentially putting the beta-cyclodextrin, the polyethylene glycol, the silicon dioxide, the mixture A mixed by the dispersion method and the rest part of anhydrous glucose into the preheated reaction kettle for mixing to obtain the soluble florfenicol powder medicament.
Further, the preheating temperature in the step S102 is 20 ℃ to 35 ℃.
Further, the preheating time in the above step S102 is 1.5 hours.
Further, the mesh diameter of the screen in the above step S103 is 40 to 60 mesh.
Further, the above step S104 is carried out for 15 to 20 minutes.
Further, the mesh diameter of the screen in the above step S105 is 10 to 15 mesh.
Further, the mixing time in the step S106 is 1 to 2.5 hours.
The invention has the beneficial effects that:
1. by adding materials such as florfenicol, beta-cyclodextrin and the like, when the florfenicol and the beta-cyclodextrin are subjected to inclusion, chemical reaction does not occur, the inclusion mainly is a physical process but is not a simple physical mixing process, the florfenicol molecules are completely or partially embedded in a cavity structure of the beta-cyclodextrin molecules to form the florfenicol beta-cyclodextrin inclusion compound, the florfenicol inclusion effect is good, and the inclusion rate is high.
2. The florfenicol slow-release taste-masking preparation prepared by the process successfully solves the problem of poor palatability of the florfenicol, masks the bitter taste of the medicament, increases the palatability and greatly improves the appetite of animals; the florfenicol slow-release taste-masking preparation successfully wraps the florfenicol in beta-cyclodextrin, so that the florfenicol can be slowly released, the slow-release effect is achieved, the action time of the florfenicol is prolonged, the curative effect of the florfenicol is improved, and the bioavailability is improved.
3. The invention utilizes the hollow structure of beta-cyclodextrin molecules to carry out molecular inclusion on the florfenicol, and simultaneously adds water-soluble surface active polymer auxiliary materials, thereby successfully improving the water solubility and bioavailability of the florfenicol, effectively covering the bitter taste of the florfenicol and improving the palatability. And the core technology of the company is improved through the development of new products, and the popularity of the company is improved.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
FIG. 1 is a flow chart of a method for preparing soluble florfenicol powder according to an embodiment of the present invention.
Detailed Description
For further explanation of the various embodiments, the drawings which form a part of the disclosure and which are incorporated in and constitute a part of this specification, illustrate embodiments and, together with the description, serve to explain the principles of operation of the embodiments, and to enable others of ordinary skill in the art to understand the various embodiments and advantages of the invention, and, by reference to these figures, reference is made to the accompanying drawings, which are not to scale and wherein like reference numerals generally refer to like elements.
According to an embodiment of the present invention, there is provided a soluble florfenicol powder.
The soluble florfenicol powder is prepared from the following raw materials in parts by mass:
5-15 parts of florfenicol, 2-5 parts of beta-cyclodextrin, 3-7 parts of polyethylene glycol, 2-6 parts of silicon dioxide, 2-5 parts of acidic auxiliary materials and 2-3 parts of sterilization ingredients.
Wherein the acidic auxiliary materials comprise the following raw material components: 1-2 parts of anhydrous citric acid and 1-3 parts of anhydrous glucose.
Wherein, the composite antioxidant comprises the following raw material components: 0.5-1 part of lactic acid methoxybenzyl aminopyrimidine and 1.5-2 parts of aminobenzene sulfonamide powder.
In order to clearly understand the technical solutions of the present invention, the following detailed descriptions of the technical solutions of the present invention are provided by specific examples.
Example one
The soluble florfenicol powder is prepared from the following raw materials in parts by mass:
5g of florfenicol, 2g of beta-cyclodextrin, 3g of polyethylene glycol, 2g of silicon dioxide, 2g of acidic auxiliary materials and 2g of sterilization ingredients.
Wherein the acidic auxiliary materials comprise the following raw material components: 1g of anhydrous citric acid and 1g of anhydrous glucose.
Wherein, the composite antioxidant comprises the following raw material components: 0.5g of trimethoprim lactate and 1.5g of aminobenzenesulfonamide powder.
The preparation method for the soluble florfenicol powder comprises the following steps:
s101, weighing 5g of florfenicol, 2g of beta-cyclodextrin, 3g of polyethylene glycol, 2g of silicon dioxide, 2g of acidic auxiliary materials and 2g of sterilization ingredients, which are required by the soluble florfenicol powder, according to the mass parts;
s102, preheating a reaction kettle prepared in advance, and preserving heat;
s103, sieving 5g of the weighed florfenicol, 0.5g of trimethoprim lactate and 1g of anhydrous citric acid in sequence;
s104, sequentially putting 5g of the screened florfenicol, 0.5g of trimethoprim lactate, 1g of anhydrous citric acid and part of anhydrous glucose into a pre-prepared dispersing device for dispersing and mixing to obtain a mixture A;
s105, sequentially sieving 2g of the weighed beta-cyclodextrin, 3g of polyethylene glycol and 2g of silicon dioxide;
s106, sequentially putting 2g of beta-cyclodextrin, 3g of polyethylene glycol, 2g of silicon dioxide, the mixture A mixed by a dispersion method and the rest part of anhydrous glucose into the preheated reaction kettle for mixing to obtain the soluble florfenicol powder medicament.
Example two
The soluble florfenicol powder is prepared from the following raw materials in parts by mass:
10g of florfenicol, 3.5g of beta-cyclodextrin, 5g of polyethylene glycol, 4g of silicon dioxide, 3.5g of acidic auxiliary materials and 2.5g of sterilization ingredients.
Wherein the acidic auxiliary materials comprise the following raw material components: 1.5g of anhydrous citric acid and 2g of anhydrous glucose.
Wherein, the composite antioxidant comprises the following raw material components: 0.75g of trimethoprim lactate and 1.75g of aminobenzenesulfonamide powder.
The preparation method of the soluble florfenicol powder comprises the following steps:
s101, weighing 10g of florfenicol, 3.5g of beta-cyclodextrin, 5g of polyethylene glycol, 4g of silicon dioxide, 3.5g of acidic auxiliary materials and 2.5g of sterilization ingredients, which are required by the soluble florfenicol powder according to the mass parts;
s102, preheating a reaction kettle prepared in advance, and preserving heat;
s103, sieving 10g of the weighed florfenicol, 0.75g of trimethoprim lactate and 1.5g of anhydrous citric acid in sequence;
s104, sequentially adding 10g of screened florfenicol, 0.75g of trimethoprim lactate, 1.5g of anhydrous citric acid and part of anhydrous glucose into a pre-prepared dispersing device for dispersing and mixing to obtain a mixture A;
s105, sequentially sieving 3.5g of the weighed beta-cyclodextrin, 5g of polyethylene glycol and 4g of silicon dioxide;
s106, sequentially putting 3.5g of beta-cyclodextrin, 5g of polyethylene glycol, 4g of silicon dioxide, the mixture A mixed by a dispersion method and the rest part of anhydrous glucose into the preheated reaction kettle for mixing to obtain the soluble florfenicol powder medicament.
EXAMPLE III
The soluble florfenicol powder is prepared from the following raw materials in parts by mass:
the florfenicol oral liquid comprises 15g of florfenicol, 5g of beta-cyclodextrin, 7g of polyethylene glycol, 6g of silicon dioxide, 5g of acidic auxiliary materials and 3g of sterilization ingredients.
Wherein the acidic auxiliary materials comprise the following raw material components: 2g of anhydrous citric acid and 3g of anhydrous glucose.
Wherein, the composite antioxidant comprises the following raw material components: 1g of lactic acid methoxybenzyl aminopyrimidine and 2g of aminobenzenesulfonamide powder.
The preparation method of the soluble florfenicol powder comprises the following steps:
s101, weighing 15g of florfenicol, 5g of beta-cyclodextrin, 7g of polyethylene glycol, 6g of silicon dioxide, 5g of acidic auxiliary materials and 3g of sterilization ingredients, which are required by the soluble florfenicol powder, according to the mass parts;
s102, preheating a reaction kettle prepared in advance, and preserving heat;
s103, sieving 15g of the weighed florfenicol, 1g of trimethoprim lactate and 2g of anhydrous citric acid in sequence;
s104, sequentially putting 15g of screened florfenicol, 1g of trimethoprim lactate, 3g of anhydrous citric acid and part of anhydrous glucose into a pre-prepared dispersing device for dispersing and mixing to obtain a mixture A;
s105, sequentially sieving 5g of the weighed beta-cyclodextrin, 7g of polyethylene glycol and 6g of silicon dioxide;
s106, sequentially putting 5g of beta-cyclodextrin, 7g of polyethylene glycol, 6g of silicon dioxide, the mixture A mixed by a dispersion method and the rest part of anhydrous glucose into the preheated reaction kettle for mixing to obtain the soluble florfenicol powder medicament.
According to the embodiment of the invention, the invention also provides a preparation method of the soluble florfenicol powder.
As shown in figure 1, in the actual production process, the preparation of the soluble florfenicol powder comprises the following steps:
step S101, weighing florfenicol, beta-cyclodextrin, polyethylene glycol, silicon dioxide, acidic auxiliary materials and sterilization ingredients required by the soluble florfenicol powder according to the mass parts;
step S102, preheating a reaction kettle prepared in advance, and preserving heat;
step S103, sequentially sieving the weighed florfenicol, trimethoprim lactate and anhydrous citric acid;
step S104, sequentially putting the screened florfenicol, the trimethoprim lactate, the anhydrous citric acid and part of anhydrous glucose into a pre-prepared dispersing device for mixing by a dispersing method to obtain a mixture A;
s105, sequentially sieving the weighed beta-cyclodextrin, polyethylene glycol and silicon dioxide;
and step S106, sequentially putting the beta-cyclodextrin, the polyethylene glycol, the silicon dioxide, the mixture A mixed by the dispersion method and the rest part of anhydrous glucose into the preheated reaction kettle for mixing to obtain the soluble florfenicol powder medicament.
In one embodiment, the preheating temperature in the step S102 is 20-35 ℃.
In one embodiment, the preheating time in step S102 is 1.5 hours.
In one embodiment, the mesh diameter of the screen in step S103 is 40-60 mesh.
In one embodiment, the mixing in step S104 is performed for 15-20 minutes.
In one embodiment, the mesh diameter of the screen mesh in the above step S105 is 10-15 mesh.
In one embodiment, the mixing time in step S106 is 1-2.5 hours.
In conclusion, by adding materials such as florfenicol, beta-cyclodextrin and the like, when the florfenicol and the beta-cyclodextrin are subjected to inclusion, chemical reaction does not occur, the inclusion mainly is a physical process but is not a simple physical mixing process, the florfenicol molecules are completely or partially embedded in a cavity structure of the beta-cyclodextrin molecules to form the florfenicol beta-cyclodextrin inclusion compound, the inclusion effect is good, and the inclusion rate is very high. The florfenicol slow-release taste-masking preparation prepared by the process successfully solves the problem of poor palatability of the florfenicol, masks the bitter taste of the medicament, increases the palatability and greatly improves the appetite of animals; the florfenicol slow-release taste masking preparation successfully wraps the florfenicol in beta-cyclodextrin, so that the florfenicol can be slowly released, the slow-release effect is achieved, the action time of the florfenicol is prolonged, the curative effect of the florfenicol is improved, and the bioavailability is improved; the florfenicol is subjected to molecular inclusion by utilizing the hollow structure of the beta-cyclodextrin molecules, and meanwhile, the water-soluble surface active polymer auxiliary material is added, so that the water solubility and the bioavailability of the florfenicol are successfully improved, the bitter taste of the florfenicol is effectively covered, and the palatability is improved. Meanwhile, the core technology of the company is improved through the development of new products, and the popularity of the company is improved.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (10)
1. The soluble florfenicol powder is characterized by being prepared from the following raw materials in parts by mass:
5-15 parts of florfenicol, 2-5 parts of beta-cyclodextrin, 3-7 parts of polyethylene glycol, 2-6 parts of silicon dioxide, 2-5 parts of acidic auxiliary materials and 2-3 parts of sterilization ingredients.
2. The soluble florfenicol powder according to claim 1, wherein the acidic adjuvant comprises the following raw material components: 1-2 parts of anhydrous citric acid and 1-3 parts of anhydrous glucose.
3. The soluble florfenicol powder as claimed in claim 2, wherein the composite antioxidant comprises the following raw material components: 0.5-1 part of lactic acid methoxybenzyl aminopyrimidine and 1.5-2 parts of aminobenzene sulfonamide powder.
4. A process for the preparation of soluble florfenicol powder, characterized in that it is used for the preparation of soluble florfenicol powder according to claim 3, comprising the steps of:
s101, weighing florfenicol, beta-cyclodextrin, polyethylene glycol, silicon dioxide, acidic auxiliary materials and sterilization ingredients required by the soluble florfenicol powder according to the mass parts;
s102, preheating a reaction kettle prepared in advance, and preserving heat;
s103, sequentially sieving the weighed florfenicol, trimethoprim lactate and anhydrous citric acid;
s104, sequentially putting the screened florfenicol, the trimethoprim lactate, the anhydrous citric acid and part of anhydrous glucose into a pre-prepared dispersing device for mixing by a dispersing method to obtain a mixture A;
s105, sequentially sieving the weighed beta-cyclodextrin, polyethylene glycol and silicon dioxide;
and S106, sequentially putting the beta-cyclodextrin, the polyethylene glycol, the silicon dioxide, the mixture A mixed by the dispersion method and the rest part of anhydrous glucose into the preheated reaction kettle for mixing to obtain the soluble florfenicol powder medicament.
5. The process for preparing soluble florfenicol powder according to claim 4, wherein the preheating temperature in the above step S102 is 20 ℃ to 35 ℃.
6. The process for preparing soluble florfenicol powder according to claim 4, wherein the preheating time in step S102 is 1.5 hours.
7. The method for preparing soluble florfenicol powder according to claim 4, wherein the mesh diameter of the screen in step S103 is 40-60 mesh.
8. The method for preparing soluble florfenicol powder according to claim 4, wherein the mixing in step S104 is performed for 15-20 minutes.
9. The method for preparing soluble florfenicol powder according to claim 4, wherein the mesh diameter of the screen mesh in the above step S105 is 10-15 mesh.
10. The process of claim 4, wherein the mixing time in step S106 is 1-2.5 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189535.8A CN112641730A (en) | 2021-02-19 | 2021-02-19 | Preparation method of soluble florfenicol powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110189535.8A CN112641730A (en) | 2021-02-19 | 2021-02-19 | Preparation method of soluble florfenicol powder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112641730A true CN112641730A (en) | 2021-04-13 |
Family
ID=75370981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110189535.8A Pending CN112641730A (en) | 2021-02-19 | 2021-02-19 | Preparation method of soluble florfenicol powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112641730A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115894944A (en) * | 2023-01-06 | 2023-04-04 | 四川科宏达集团有限责任公司 | Modified functional surfactant derivative, preparation method and application |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090062397A1 (en) * | 2007-04-27 | 2009-03-05 | Schering-Plough Animal Health Corporation | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
| CN102160854A (en) * | 2011-04-15 | 2011-08-24 | 广东养宝生物制药有限公司 | Cyclodextrin-included florfenicol quick-release water-soluble powder preparation and preparation method thereof |
| CN107519135A (en) * | 2017-09-30 | 2017-12-29 | 中牧实业股份有限公司黄冈动物药品厂 | A kind of preparation method of high water-soluble florfenicol powder |
| CN108096191A (en) * | 2017-12-29 | 2018-06-01 | 河北利华药业有限公司 | Florfenicol pre-mixing agent and preparation method thereof |
| CN108743541A (en) * | 2018-06-24 | 2018-11-06 | 王琴 | Water-soluble veterinary drug preparation and preparation method thereof |
| CN110787131A (en) * | 2019-12-13 | 2020-02-14 | 河北远征药业有限公司 | Preparation method of florfenicol soluble powder preparation |
| CN110882220A (en) * | 2019-09-27 | 2020-03-17 | 洛阳惠中兽药有限公司 | Preparation method of water-soluble florfenicol powder and water-soluble florfenicol powder prepared by same |
| CN110917141A (en) * | 2018-09-20 | 2020-03-27 | 临沂文一诺知识产权运营有限公司 | Method for preparing florfenicol soluble powder medicament |
| CN111588698A (en) * | 2020-06-23 | 2020-08-28 | 南京大方生物工程有限公司 | Florfenicol powder for improving water solubility and preparation method and application thereof |
-
2021
- 2021-02-19 CN CN202110189535.8A patent/CN112641730A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090062397A1 (en) * | 2007-04-27 | 2009-03-05 | Schering-Plough Animal Health Corporation | Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins |
| CN102160854A (en) * | 2011-04-15 | 2011-08-24 | 广东养宝生物制药有限公司 | Cyclodextrin-included florfenicol quick-release water-soluble powder preparation and preparation method thereof |
| CN107519135A (en) * | 2017-09-30 | 2017-12-29 | 中牧实业股份有限公司黄冈动物药品厂 | A kind of preparation method of high water-soluble florfenicol powder |
| CN108096191A (en) * | 2017-12-29 | 2018-06-01 | 河北利华药业有限公司 | Florfenicol pre-mixing agent and preparation method thereof |
| CN108743541A (en) * | 2018-06-24 | 2018-11-06 | 王琴 | Water-soluble veterinary drug preparation and preparation method thereof |
| CN110917141A (en) * | 2018-09-20 | 2020-03-27 | 临沂文一诺知识产权运营有限公司 | Method for preparing florfenicol soluble powder medicament |
| CN110882220A (en) * | 2019-09-27 | 2020-03-17 | 洛阳惠中兽药有限公司 | Preparation method of water-soluble florfenicol powder and water-soluble florfenicol powder prepared by same |
| CN110787131A (en) * | 2019-12-13 | 2020-02-14 | 河北远征药业有限公司 | Preparation method of florfenicol soluble powder preparation |
| CN111588698A (en) * | 2020-06-23 | 2020-08-28 | 南京大方生物工程有限公司 | Florfenicol powder for improving water solubility and preparation method and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115894944A (en) * | 2023-01-06 | 2023-04-04 | 四川科宏达集团有限责任公司 | Modified functional surfactant derivative, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI351969B (en) | Azithromycin dosage forms with reduced side effect | |
| JP4922948B2 (en) | Balnemulin salt with organic acid | |
| DE4100920A1 (en) | ACTIVE SUBSTANCE PREPARATION FOR ORAL ADMINISTRATION TO Ruminants | |
| CN104996737B (en) | A kind of coating preparation method of fodder acidulant | |
| CN108836950B (en) | Preparation method of protein sporopollen oral microcapsule | |
| CN112641730A (en) | Preparation method of soluble florfenicol powder | |
| KR20040073504A (en) | Methods for wet granulating azithromycin | |
| CN106822033A (en) | The capsule core material and its micro-capsule of drug containing are prepared as capsule core material with maize cob meal | |
| CN104922073A (en) | Soluble florfenicol powder and preparation method thereof | |
| CN106721055A (en) | Feeding coating compound acidulant and preparation method thereof | |
| HU179896B (en) | Process for instrument for applying medicaments for ruminants | |
| CN112244163A (en) | Antibiotic-free piglet feed additive and preparation method and application method thereof | |
| CN106074543A (en) | A kind of water solublity synergistic composition containing amoxicillin and application thereof | |
| CN103768026A (en) | Water-soluble micro-powder containing amoxicillin and preparation method thereof | |
| CN105053557B (en) | A kind of coating preparation method of phosphoric acid micropore acidulant particulate material | |
| CN109430674B (en) | Preparation method of N-succinyl chitosan immobilized nisin and perilla oil film | |
| EP3554283B1 (en) | Glycerin- and protein-based foam candy products with probiotic bacteria | |
| CN113171358A (en) | Pet chewing gum based on alginate soft capsules | |
| CN107837235A (en) | It is coated with the preparation method of Enrofloxacin soluble powder | |
| JP3890086B2 (en) | Composition for preventing and treating infectious diarrhea | |
| CN108478588B (en) | Tilmicosin slow-release enteric solvent and preparation method thereof | |
| KR101695440B1 (en) | A Method for manufacturing a biodegradable polymeric microsphere type sustained-release formulation having comprising a fluoroquinolone antibiotics | |
| CN113230233A (en) | Florfenicol solid dispersion inclusion microcapsule and preparation method and application thereof | |
| CN109907072B (en) | Bacteria-carrying nano chitosan livestock house disinfectant and preparation method and application thereof | |
| US9358254B2 (en) | Pharmaceutical use of a composition including a carbonaceous material and an active particle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210413 |